Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in AQP4-IgG Seropositive NMOSD
NCT05504694Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jun 2022
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tangdu Hospital. Primary endpoint: Annual Relapse Rate at 12 months. Started Jun 2022; status: recruiting.
02
Drugs
ofatumumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05504694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504694.